Evidence map›Paper›PMID 41909755›Full record

ArticleActa pharmaceutica Sinica. B2026

Heterocyclic modified paclitaxel prodrug nanoassemblies for stimuli-responsive delivery

Mingyang Han, Hezhen Xu, Jun Yuan, Wenxiao Li, Hao Zhang, Hongkai Fang, Zhiyu Kuang, Yuanhao Yu, Danping Wang, Zhenzhen Zhao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mingyang HanWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Hezhen XuWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jun YuanWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Wenxiao LiWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Hao ZhangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Hongkai FangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhiyu KuangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yuanhao YuWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Danping WangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhenzhen ZhaoDepartment of Pharmacy, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China.
Cong LuoWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Bingjun SunWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jin SunWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prodrug nanoassemblies offer an innovative approach to drug delivery, but their lysosomal entrapment often impairs drug release. Notably, tertiary amine structures can undergo protonation reactions, thereby facilitating lysosomal escape through the proton sponge effect. In this study, we developed three novel paclitaxel prodrug nanoassemblies (PTX-SS-NO NPs, PTX-SS-CC NPs and PTX-SS-NC NPs) featuring distinct heterocyclic tertiary amine structures to investigate structure-activity relationships in lysosomal escape and drug delivery. Among them, PTX-SS-NC NPs demonstrated excellent lysosomal escape capability, enabling rapid drug release into the cytosol. Systematic evaluation revealed that the PTX-SS-NC NPs exhibited optimized pharmacokinetics and significant tumor accumulation, further contributing to their strong antitumor efficacy. Our findings establish heterocyclic tertiary amines as crucial design elements for overcoming lysosomal entrapment and optimizing chemotherapeutic prodrug nanoassemblies.

Indexed as

Cancer therapyDrug deliveryHeterocyclic tertiary amineLysosomal escapeModular designPaclitaxel prodrug nanoassembliesProton sponge effectStimuli-responsive

Identifiers

PMID41909755
PMCPMC13031148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.